Lyophilizable and enhanced compacted nucleic acids
Patent Number: US2003078229
Publication date: 2003-04-24
Inventor(s): COOPER MARK J [US]; PASUMARTHY MURALI K [US]; KOWALCZYK TOMASZ H [US]; COSTELLO MAUREEN [US]
Applicant(s): COPERNICUS THERAPEUTICS INC [US]
Requested Patent: US2003078229
Application Number: US20020305078 20021127
Priority Number(s): US20020305078 20021127; US20010867693 20010531; US20010287419P 20010501; US20000207949P 20000531
IPC Classification: A61K48/00; C12Q1/68; C07H21/04
EC Classification: A61K9/00M14, A61K9/51, A61K48/00, C12N15/88, G01N21/51
Equivalents:
Abstract
Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body. Moreover, counterions such as acetate can protect compacted nucleic acid complexes from adverse effects of lyophilization
Data supplied from the esp@cenet database - l2
Votes:8
Comments: 0